Tolymbekova A, Lezina L (2025) CD320 receptor and vitamin B12 as potential targets for anti-cancer therapy. Int J Mol Sci 26(12):5652. doi: 10.3390/ijms26125652 PMID: 40565117
Objective: To develop therapies discriminating between healthy and cancerous cells to prevent unwanted toxicity of anticancer agents.
Summary: One possible method is to target proteins overexpressed in cancer but not in normal cells. CD320 is a receptor responsible for the uptake of the transcobalamin-bound fraction of vitamin B12 (cobalamin), which is necessary for DNA synthesis, and thus, cell proliferation. CD320 was shown to be overexpressed in many cancers and its potential role as an early cancer biomarker was confirmed in several studies.
Usage: In CD320-overexpressing HEK293 cells, a 2.5 nM concentration of monoclonal antibodies conjugated with saporin was enough to induce a 100% inhibition of proliferation, while in normal HEK293 cells, the same concentration of antibodies induced approximately 50% inhibition of cell proliferation.
Related Products: Saporin (Cat. #PR-01)